Current market catalysts

8-K filing — Designer Brands Inc. (DBI)

Filed: 2026-09-10 AccNo: 0001319947-26-000048 Size: 605 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Chemours, DuPont De Nemours And Corteva Reach Settlement State Of North Carolina And 11 Local Entities; Overall Settlement Payments Total $455M Over 15 Years, With Chemours' 50% Share Of Payments Of ~$180M On NPV Basis Covered By Existing Accruals

The Chemours Company (NYSE:CC) (the "Company") today announced that, along with DuPont de Nemours, Inc. ("Dupont") and Corteva, Inc. ("Corteva"), it has entered into a settlement (the

Needham Reiterates Buy on AeroVironment, Maintains $225 Price Target

Needham analyst Austin Bohlig reiterates AeroVironment (NASDAQ:AVAV) with a Buy and maintains $225 price target.

Designer Brands Raises FY2026 GAAP EPS Guidance from $0.28-$0.38 to $0.47-$0.52 vs $0.39 Est; Raises FY2026 Sales Guidance from $2.868B-$2.926B to $2.897B-$2.926B vs $2.909B Est

Designer Brands (NYSE:DBI) raises FY2026 GAAP EPS guidance from $0.28-$0.38 to $0.47-$0.52 vs $0.39 analyst estimate. Raises FY2026 sales outlook from $2.868 billion-$2.926 billion to $2.897 billion-$2.926 billion vs

8-K filing — Chemours Co (CC)

Filed: 2026-09-10 AccNo: 0001627223-26-000029 Size: 926 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Designer Brands Q2 Adj. EPS $0.34 Beats $0.26 Estimate, Sales $730.631M Miss $744.660M Estimate

Designer Brands (NYSE:DBI) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.26 by 30.77 percent. This is unchanged from the same period last year. The company reported

1-800-Flowers.com Q4 Adj. EPS $(0.80) Misses $(0.69) Estimate, Sales $293.118M Miss $293.596M Estimate

1-800-Flowers.com (NASDAQ:FLWS) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.69) by 15.94 percent. This is a 15.94 percent decrease over losses of $(0.69) per share

Needham Maintains Buy on Cooper Companies, Lowers Price Target to $73

Needham analyst David Saxon maintains Cooper Companies (NASDAQ:COO) with a Buy and lowers the price target from $86 to $73.

The $100 Oil Tipping Point: The Economy Is Running Out of Shock Absorbers

Oil hits $100 as the US-Iran war squeezes markets. Will AI growth prevent a recession, or is stagflation next? Read the IMF warning.

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.

Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments

These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected

HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.

'White House copper tariff plan stalls amid affordability concerns, sources say' - Reuters Exclusive

https://www.reuters.com/world/us/white-house-copper-tariff-plan-stalls-amid-affordability-concerns-sources-say-2026-09-10/

Senator Chris Murphy Sounds Alarm on AI Race, Backs Anthropic Researcher's Warning: 'AI Companies In a Blind Race to Build a Death Machine First'

Murphy backs Anthropic researcher’s warning on AI’s dangerous race toward superintelligence and calls for government oversight.

HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.

'Nasdaq Invests in Kraken Parent Payward at $21 Billion Valuation' - Bloomberg

https://www.bloomberg.com/news/articles/2026-09-10/nasdaq-invests-in-kraken-parent-payward-at-21-billion-valuation

Akamai Expands Technology Collaboration With MuleSoft Extending Governance Across Apis, Agents, And MCP Servers

Expanded bidirectional integration connects Akamai API Security intelligence with Agent Fabric, extending governance across APIs, agents, and MCP serversHelps organizations discover, understand, and govern APIs and MCP

Elon Musk's Boring Company Raises $3 Billion at $23 Billion Valuation, Plans Over 93 Miles of UAE Tunnels

Elon Musk's The Boring Co. raises $3B from UAE-led investors, reaching a $23B valuation to build 150km+ of tunnels.

Empire Co Q1 EPS $1.04 Beats $0.96 Estimate, Sales $8.475B Miss $8.543B Estimate

Empire Co (TSX:EMP) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.96 by 8.33 percent. This is a 14.29 percent increase over earnings of $0.91 per share from the same

Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026

In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline data readout remains on timeline for the second half of 2026. As part of the nonclinical characterization of certain

Stifel Reinstates Hold on Antero Resources, Announces $42 Price Target

Stifel analyst David Deckelbaum reinstates Antero Resources (NYSE:AR) with a Hold and announces $42 price target.

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.

Trump Pledges $5,000 Checks if GOP Wins Midterms — Here's the Price Tag

Trump Media & Technology Group is trending after President Trump promised a $5,000 "dividend" if Republicans win Congress in the midterms.

AI Could Become Far More Powerful Before It Shows Up in GDP — Box CEO Says Businesses Are Still Bound by the ‘Laws of Corporate Physics’

Box CEO Aaron Levie says AI may advance faster than its GDP impact as businesses face data, workflow, organizational and adoption hurdles.

8-K filing — SOLAREDGE TECHNOLOGIES, INC. (SEDG)

Filed: 2026-09-10 AccNo: 0001178913-26-004477 Size: 184 KB Item 7.01: Regulation FD Disclosure

Stifel Reinstates Buy on Devon Energy, Announces $61 Price Target

Stifel analyst David Deckelbaum reinstates Devon Energy (NYSE:DVN) with a Buy and announces $61 price target.

Elevance Health Affirms FY2026 GAAP EPS expected to be more than $20.10 vs $20.26 Est

Elevance Health (NYSE:ELV) Affirms FY2026 expected to be more than $20.10 vs $20.26 Est..

Elevance Health Affirms FY2026 Adj EPS expected to be more than $27.00 vs $26.91 Est

Elevance Health (NYSE:ELV) Affirms FY2026 expected to be more than $27.00 vs $26.91 Est..

HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.

'Major Novartis shareholder calls for board shake-up after drug trial setbacks' - Reuters Exclusive Interview